Navigation Links
Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads
Date:9/22/2010

Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads -- BERGISCH GLADBACH, Germany, September 22, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services Click to view news release full screen  

Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads

 

BERGISCH GLADBACH, Germany, September 22, 2010 /PRNewswire/ -- Miltenyi Biotec announces the worldwide first and exclusive release of the Anti-GLAST (ACSA-1) MicroBead Kit. Isolation of viable GLAST-expressing astrocytes is now possible within one hour using the first commercially available antibody against an extracellular surface epitope of GLAST. Magnetic cell separation with MACS(R) Technology is the method of choice for the specific isolation of viable cells. A prerequisite for specific cell isolation is the availability of antibodies directed against a specific cell surface antigen. Suitable antibodies against extracellular markers on the astrocyte cell surface were not available until recently, and astrocytes had to be isolated by time-consuming methods, such as generation of astrocyte cultures, which even differ considerably from astrocytes in vivo, or by transgenic approaches.

The new anti-GLAST (ACSA-1) antibody (astrocyte cell surface antigen 1; ACSA-1) recognizes an extracellular epitope of the astrocyte-specific glutamate transporter GLAST (EAAT1), and it shows specific and sensitive labeling of GLAST-positive cells in flow cytometry, immunohistochemistry, and immunocytochemistry.

"The Anti-GLAST (ACSA-1) MicroBead Kit provides the first tool for the straightforward isolation of astrocytes from dissociated brain tissue, and enables the separation of astrocytes based on their expression of GLAST," says Dr. Melanie Jungblut, the responsible R&D Project Manager. "The kit allows for the direct isolation of viable primary astrocytes within one hour, and achieves high purity by minimizing contamination by other cells."

The Anti-GLAST (ACSA-1) MicroBead Kit is exclusively available from Miltenyi Biotec.

About Miltenyi Biotec

Miltenyi Biotec's company mission is to improve scientific understanding and medical progress by providing products and services for cellular therapies. More than 1,100 employees worldwide develop, produce and sell products for biomedical research and clinical applications. The renowned MACS Technology for magnetic separation of cells has become a standard technology in research laboratories worldwide.

Press contact: Prof. Dr. Uwe A. O. Heinlein Corporate Communications, Miltenyi Biotec GmbH Friedrich-Ebert-Strasse 68, 51429 Bergisch Gladbach, Germany Phone: +49-2204-8306-6590 E-mail: uweh@miltenyibiotec.de .
'/>"/>

SOURCE Miltenyi Biotec GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
2. Directors Forum: PEPFAR and the Global AIDS Response
3. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
4. West Pharmaceutical Services, Inc. Appoints New Director
5. Pivotal MIRCERA(R) Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
6. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
7. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
10. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
11. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):